Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Structure Therapeutics Inc. - American Depositary Shares
(NQ:
GPCR
)
39.27
+0.13 (+0.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Structure Therapeutics Inc. - American Depositary Shares
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
June 07, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
June 05, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
June 03, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
June 03, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
May 09, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
March 08, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
March 08, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
IPO watch 2024: Which new stocks will hit the market?
January 08, 2024
Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies.
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
December 18, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
November 14, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
October 19, 2023
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
September 29, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
September 29, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
August 10, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
August 03, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
June 07, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics to Present at Jefferies Healthcare Conference
May 31, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
May 25, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
May 18, 2023
Posters include data across biomarker, translation and clinical studies supporting development of cardiopulmonary programs LTSE-2578 and ANPA-0073
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 30, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
There's a Lot to Love About Mineralys' Valentine's Day IPO
February 13, 2023
MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
February 07, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.